WO2001047544A1 - Preparation de seringue prealablement remplie de proteine et procede de stabilisation - Google Patents

Preparation de seringue prealablement remplie de proteine et procede de stabilisation Download PDF

Info

Publication number
WO2001047544A1
WO2001047544A1 PCT/JP2000/009309 JP0009309W WO0147544A1 WO 2001047544 A1 WO2001047544 A1 WO 2001047544A1 JP 0009309 W JP0009309 W JP 0009309W WO 0147544 A1 WO0147544 A1 WO 0147544A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
prefilled syringe
resin
csf
preparation
Prior art date
Application number
PCT/JP2000/009309
Other languages
English (en)
Japanese (ja)
Inventor
Yoshimi Imaeda
Daisuke Kameoka
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to AU22275/01A priority Critical patent/AU2227501A/en
Publication of WO2001047544A1 publication Critical patent/WO2001047544A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M5/31513—Piston constructions to improve sealing or sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0222—Materials for reducing friction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Definitions

  • the present invention relates to a protein prefilled syringe preparation and a method for stabilizing the same.
  • the present invention relates to a protein prefilled syringe preparation which is easy to handle and stable for a long period of time. More specifically, the present invention relates to a stable protein prefilled syringe preparation comprising an elastic body coated with a resin on at least a protein solution contact surface. The invention further relates to a method for stabilizing a protein prefilled syringe formulation. Viewing technology
  • protein prefilled syringe preparations contain diluents, solubilizers, tonicity agents, excipients, pH adjusters, buffers, sulfur-containing reducing agents, antioxidants, etc., in addition to the active ingredient protein. And provided in the market in a syringe. Satisfactory conditions for protein prefilled syringe preparations include (1) that protein products are stable under long-term storage conditions, (2) that they have heat resistance and pressure resistance that can withstand the conditions used for sterilization, 3) It has chemical resistance, (4) it has excellent sealing properties, and (5) it has good plunger slidability.
  • a syringe has been required to have a hermetic seal, and in order to satisfy this requirement, a rubber sealing stopper made of a single rubber material having the highest hermeticity has been used.
  • the solution formulation and the rubber stopper are always in contact with the drug in the vial formulation, and the chemical effect of the drug from the rubber stopper is large, resulting in deterioration of the drug product.
  • maintaining long-term stability is difficult. Therefore, there is a demand for the development of a protein prefilled syringe formulation that can be stored for a long period of time, but a product that satisfies all the above requirements has not been developed. Disclosure of the invention
  • the present inventors have studied the above problems from various factors, and have found that a rubber stopper of a syringe used for a prefilled syringe formulation has an adverse effect on protein stabilization.
  • a rubber stopper of a syringe used for a prefilled syringe formulation has an adverse effect on protein stabilization.
  • there are variations in the surface treatment of rubber stoppers which greatly affects the residual rate of protein solution preparations depending on the production lot of rubber stoppers, and the variation in residual rates among individuals within the same lot is large. I found that.
  • the present inventors have found that laminating a rubber stopper with Teflon can greatly contribute to the improvement of protein stability, particularly when the protein is granulocyte colony stimulating factor (G-CSF). That is, the present inventors have completed the present invention by finding that when a plastic film is laminated on the surface of a stopper made of a rubber material alone, a high content of protein can be retained for an extremely long time.
  • G-CSF granulocyte colony stimulating factor
  • the present invention provides a stable protein prefilled syringe preparation comprising an elastic body coated with a resin on at least the protein solution contact surface.
  • the present invention provides the above-mentioned protein prefilled syringe preparation, comprising a stopper having a resin film laminated on at least a protein solution contact surface.
  • the present invention provides the protein prefilled syringe preparation, wherein the resin is selected from polyethylene, polypropylene, polycarbonate, polyester, and fluororesin. I will provide a.
  • the present invention provides the protein prefilled syringe preparation, wherein the resin is a fluororesin.
  • the present invention provides the above protein prefilled syringe formulation, wherein the resin is polytetrafluoroethylene.
  • the present invention provides the above-mentioned protein pre-filled syringe preparation, wherein the protein is a recombinant protein.
  • the present invention provides the above protein prefilled syringe formulation, wherein the protein is erythropoietin.
  • the present invention provides the above-mentioned protein pre-filled syringe formulation, wherein the protein is a granulocyte colony stimulating factor.
  • the present invention provides the above protein pre-filled syringe preparation, wherein the protein is a protein having a sugar chain.
  • the present invention provides a method for stabilizing a protein prefilled syringe formulation, which comprises at least filling and storing a protein solution formulation in a syringe provided with an elastic body coated with a resin on the protein solution contact surface.
  • the material of the syringe used in the present invention may be a material known in the art, and may be glass or resin.
  • Suitable resins include polymethylpentene resin, polypropylene resin, propylene-ethylene copolymer resin, polyester resin, polyethersulfone resin, polysulfone resin, or any of the above resins and polyamide resin, polyvinyl alcohol resin, ethylene vinyl acetate. It is preferable to use a resin obtained by laminating two or more layers of a resin selected from a resin and a resin.
  • Particularly preferred resin materials for protein solution preparations include those described in Japanese Patent Application No. 11-254896.
  • PE polyethylene
  • PP polypropylene
  • PET polyethylene terephthalate
  • PCT polycarbonate
  • polyethylene methacrylate is preferably made of, for example, silicone such as lacyclododecene or a derivative thereof.
  • Cyclopentyl residue or substituted cyclopentyl residue was inserted into the molecular chain by polymerization of ethylene- or propylene with ring-opening polymer and its hydrogenated product, cycloolefin such as norbornene or tetracyclododecene or its derivative, and ethylene or propylene. It is a resin that is a copolymer.
  • the cycloolefin includes monocyclic and polycyclic ones.
  • Preferred is a thermoplastic norportene resin or a thermoplastic tetracyclododecene resin.
  • examples of the thermoplastic norbornene-based resin include a ring-opened polymer of a norbornene-based monomer, a hydrogenated product thereof, an addition-type polymer of a norbornene-based monomer, and an addition-type polymer of a norbornene-based monomer and an olefin. I can do it.
  • thermoplastic tetracyclododecene resin examples include a ring-opened polymer of a tetracyclododecene monomer, a hydrogenated product thereof, an addition polymer of a tetracyclododecene monomer, and a tetracyclododecene monomer.
  • An addition type polymer of a decene monomer and an olefin is exemplified.
  • the elastic body used in the present invention is used as a stopper (slider) of a syringe and a rubber stopper for sealing, and is preferably made of a rubber body.
  • the elastic body can also be manufactured using any known rubber elastic body used for pharmaceutical containers and medical equipment, and further copolymerized with natural rubber, isoprene rubber, butadiene rubber, butyl rubber, and divinyl benzene.
  • thermoplastic elastomer As a thermoplastic elastomer, there is a technique of using a styrene-butadiene copolymer and a hydrogenated product of the copolymer as a plug for a pharmaceutical container (Japanese Patent Application Laid-Open No. 59-289695, Publication No. 57-266782, Japanese Patent Publication No. Hei 2-424296). Also, a technology in which a mixture of a thermoplastic elastomer and an isoprene-isobutylene copolymer is used as a rubber stopper (Japanese Patent Application Laid-Open No.
  • a protein solution contact surface of the elastic body is coated with a resin.
  • a coating method various methods known to those skilled in the art, such as lamination (lamination) with a resin film or spraying (coating) of a resin, can be used.
  • the resin used in the present invention any resin which is inert to the protein solution preparation filled in the prefilled syringe can be used.
  • polyethylene, polypropylene, polycarbonate, polyester, fluororesin and the like can be mentioned.
  • fluororesins such as polytetrafluoroethylene (PTF E: Teflon (registered trademark)), tetrafluoroethylene-ethylene copolymer (E TFE), and tetrafluoroethylene-hexane.
  • PPF E Teflon (registered trademark)
  • E TFE tetrafluoroethylene-ethylene copolymer
  • tetrafluoroethylene-hexane tetrafluoroethylene-hexane.
  • PCTFE polychloro trifluoroethylene
  • PTFE polytetrafluoroethylene
  • These resins are preferably used as a sheet or a film, and the thickness is not particularly limited, but
  • the elastic body used for the protein prefilled syringe preparation of the present invention is usually produced by compression molding using the above rubber composition and a resin film.
  • a stopper is disclosed in, for example, JP-A-10-248929 and JP-A-10-314305.
  • Proteins used as an active ingredient in the present invention include, for example, hematopoietic factors such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EP ⁇ ), and tropopoetin; Cytochromes such as IL-1 and IL-6, monoclonal antibodies, tissue plasminogen-activating factor (TPA), perokinase, serum albumin, blood coagulation factor VIII, lebutin, insulin , Including but not limited to, stem cell growth factor (SCF).
  • G-CSF granulocyte colony-stimulating factor
  • GM-CSF granulocyte macrophage colony-stimulating factor
  • EP ⁇ erythropoietin
  • TPA tissue plasminogen-activating factor
  • SCF stem cell growth factor
  • hematopoietic factors such as EP ⁇ , G-CSF, and thrombop
  • the protein used as an active ingredient in the present invention is a protein having substantially the same biological activity as that of a biologically active protein of a mammal, particularly a human, and is obtained from a naturally-occurring protein or a recombinant gene. Preferred are those obtained by the gene recombination method.
  • the protein obtained by the genetic recombination method is unstable compared to the natural protein, and it is preferable to use the preparation of the present invention.
  • Proteins obtained by the genetic recombination method include those having the same amino acid sequence as the natural protein, or those having one or more of the amino acid sequences deleted, substituted, or added and having the biological activity. Including.
  • proteins include those chemically modified with PEG and the like.
  • Examples of the protein used as an active ingredient in the present invention include a protein having a sugar chain.
  • the origin of the sugar chain is not particularly limited, but a sugar chain added to mammalian cells is preferable.
  • Mammalian cells include, for example, Chinese hamster ovary cells (CHO cells), BHK cells, COS cells, human-derived cells and the like, among which CHO cells are most preferred.
  • EP ⁇ may be produced by any method, extracted from human urine by various methods, separated and purified, using a genetic engineering technique (for example, according to Japanese Unexamined Patent Publication No. Sho 61-12288), hamster ovary cells (CHO), BHK cells, COS cells, human-derived cells, and the like, which are extracted and separated and purified by various methods, are used. Furthermore, it includes EPO chemically modified by PEG or the like (see International Patent Application Publication No. W090 / 12874). Furthermore, EPO with no sugar chain is chemically modified with PEG or the like.
  • EPO analogs that have been modified to increase the number of one or more glycosylation sites at the N-linked carbohydrate chain binding site or the O-linked carbohydrate chain binding site in the amino acid sequence of EPO (eg, (See Kaihei 8—151398, Tokuhei 8-506023). Further, the amount of sugar chains may be increased by increasing the content of sialic acid or the like without changing the number of sugar chain binding sites.
  • any G-CSF can be used as long as it is highly purified G-CSF.
  • the G-CSF in the present invention may be produced by any method, such as those obtained by culturing a cell line of human tumor cells and extracting and separating and purifying it from various cells, or E. coli by genetic engineering techniques. Bacteria; Listeria monocytogenes; Chinese hamster ovary (CH ⁇ ) cells, C127 cells, COS cells, and other animal-derived culture cells that are extracted and purified by various methods. Can be Like Alternatively, it is produced by E. coli, yeast, or CHO cells using a genetic recombination method. Most preferably, it is produced by a genetic modification method using CH ⁇ ⁇ ⁇ cells. Furthermore, G-CSF chemically modified with PEG or the like is also included (see International Patent Application Publication No. WO 90/12874).
  • the monoclonal antibody may be produced by any method.
  • Monoclonal antibodies are basically immunized with a sensitizing antigen according to a usual immunization method using a known technique, and the obtained immune cells are fused with a known parent cell by a normal cell fusion method.
  • the monoclonal antibody is not limited to the monoclonal antibody produced by the hybridoma, and includes a chimeric antibody artificially modified for the purpose of, for example, reducing the xenoantigenicity to humans.
  • a reshaped (reshaped) humanized antibody can also be used in the present invention. This is obtained by replacing the complementarity-determining region of a human antibody with the complementarity-determining region of a non-human mammal, for example, a mouse antibody, and a general gene recombination technique is also known. Using the known method, a reshaped humanized antibody useful in the present invention can be obtained.
  • a reshaped humanized antibody is a humanized PM-1 (hPM-1) antibody which is an anti-IL-16 receptor humanized antibody (International Patent Application Publication No. WO 92-19759).
  • the antibodies of the present invention also include human antibodies produced by known techniques using transgenic animals and the like.
  • the present invention can be applied to antibody fragments (for example, Fab, F (ab) 2, etc.) and modified antibodies (for example, single-chain antibodies, etc.).
  • antibody fragments for example, Fab, F (ab) 2, etc.
  • modified antibodies for example, single-chain antibodies, etc.
  • chimeric antibodies, humanized antibodies, antibody fragments, and modified antibodies are more unstable than natural antibodies, and therefore it is preferable to use the formulations of the present invention.
  • the protein preparation of the present invention may contain a diluent, a solubilizing agent, a tonicity agent, an excipient, a pH adjuster, a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, etc. Good.
  • a solubilizing agent polyethylene glycol; dextran, mannitol, sorbitol, inositol, glucose, flak, and lac!
  • You can use sugars such as sucrose, xylose, mannose, maltose, sucrose, and raffinose.
  • sulfur-containing reducing agent examples include N-acetyl cysteine, N-acetyl homocystine, thioctic acid, thiodiglycol, thioethanolamine, thiodaricerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, and dal.
  • sulfur-containing reducing agent examples include N-acetyl cysteine, N-acetyl homocystine, thioctic acid, thiodiglycol, thioethanolamine, thiodaricerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, and dal.
  • sulfur-containing reducing agent examples include N-acetyl cysteine, N-acetyl homocystine, thioctic acid, thiodiglycol, thioethanolamine, thiodaricerol, thiosorbitol,
  • antioxidants include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, ⁇ -tocopherol, tocopherol acetate, L-ascorbic acid and its salts, L-ascorbic acid palmitate, and L-ascorbic acid Chelating agents such as stearate, sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or disodium ethyl diamine tetraacetate (EDTA), sodium pyrophosphate, sodium metaphosphate and the like.
  • EDTA disodium ethyl diamine tetraacetate
  • inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate, and sodium hydrogen carbonate
  • solution preparations such as organic salts such as sodium citrate, potassium citrate, and sodium acetate. It may contain components that are usually added.
  • the protein solution preparation of the present invention may further contain an appropriate stabilizer for each protein, and the stabilizer includes a surfactant (for example, sorbitan fatty acid ester or glycerin fatty acid ester which is a nonionic surfactant).
  • a surfactant for example, sorbitan fatty acid ester or glycerin fatty acid ester which is a nonionic surfactant.
  • the stable protein prefilled syringe preparation of the present invention is usually administered by parenteral administration route, for example, injection (subcutaneous or intravenous injection), transdermal, transmucosal, nasal, etc., but oral administration is also possible.
  • parenteral administration route for example, injection (subcutaneous or intravenous injection), transdermal, transmucosal, nasal, etc., but oral administration is also possible.
  • the amount of protein contained in the stable protein prefilled syringe formulation of the present invention can be determined according to the protein used, the type of disease to be treated, the severity of the disease, the age of the patient, and the like.
  • 0.01 g / m1 or more, preferably 0.1 gZm1 or more, more preferably 1 gZm1 or more, more preferably 10 / ig Zm1 or more, further preferably 50 g / m Contains 1 or more proteins.
  • a prefilled syringe solution preparation it contains 0.1 gZml or more, preferably 1 / xg noml or more, more preferably 10 g / m1 or more, and still more preferably 50 gZm1 or more.
  • the amount of EP ⁇ in the solution formulation is generally between 100 and 500 000 I UZm, preferably between 200 and 100000 I UZm and more preferably between 750 and 72000 1 U / m 1.
  • G-CSF it is generally l to 1000 g / m 1, preferably 10 to 800 // g Zm, and more preferably 50 to 500 / ig / m 1.
  • the final administration concentration is generally 0.1 to 20 OmgZm, preferably 1 to 20 OmgZm. ⁇ 12 Omg / m1.
  • the protein prefilled syringe formulation of the present invention can be prepared by dissolving these components in an aqueous buffer known in the field of solution formulation, such as phosphate and Z or citrate buffers.
  • the phosphate buffer is preferably a sodium monohydrogen phosphate sodium dihydrogen phosphate system
  • the citrate buffer is preferably a sodium citrate buffer solution.
  • a buffer such as a glycine buffer or a histidine buffer may be used.
  • the evening protein prefilled syringe preparation of the present invention is a erythrocyte poetin solution preparation
  • a nonionic surfactant for example, polysorbate 80, polysorbate 20
  • an isotonic agent It preferably contains, for example, sodium chloride
  • a stabilizer eg, an amino acid, preferably L-histidine
  • the preparation contains G-CSF, a nonionic surfactant (for example, polysorbate 80, polysorbate 20), and if necessary, a diluent.
  • G-CSF a nonionic surfactant
  • the anti-IL16 receptor humanized antibody is preferably used in a glycine buffer and a Z or histidine buffer. Dissolved in a buffer solution such as a liquid, and other nonionic surfactants (for example, polysorbate 80, polysorbate 20), and if necessary, diluents, dissolution aids, isotonic agents, excipients, and pH adjusters. It preferably contains a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like, and has a pH of 5 to 8.
  • a buffer solution such as a liquid, and other nonionic surfactants (for example, polysorbate 80, polysorbate 20), and if necessary, diluents, dissolution aids, isotonic agents, excipients, and pH adjusters. It preferably contains a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like, and has a pH of 5 to 8.
  • a stable protein pre-filled syringe formulation pre-filled in a syringe equipped with a stopper in which the plastic film of the present invention was laminated at least on the protein solution contact surface was tested using G-CSF, as shown in Examples described later. Even after a 2-week accelerated test at 40 ° C, the G-CSF retention rate is much better than that of a non-laminated stopper. Or 6 months at 25 ° C, 1 Even after long-term storage at 0 ° C for 1 year, it shows good G-CSF retention. Also, if the protein is EPO, even after accelerated tests at 50 ° C-2 weeks or 40 ° C-1 month, or at 6 months at 25 ° C and 1 year at 10 ° C Very good EPO persistence after storage.
  • the present invention also provides a method for stabilizing a protein prefilled syringe formulation, which comprises filling and storing a protein solution formulation in a syringe provided with a stopper having a plastic film laminated on at least the protein solution contact surface.
  • the stabilization in the present invention depends on the type of protein to be filled. For example, in the case of a G-CSF solution preparation (containing 12 G-CSF), this is stored at, for example, 40 ° C for 2 weeks or more. At that time, it means that the residual ratio of G-CSF is maintained at 75% or more, preferably 80% or more, and more preferably 85% or more.
  • the residual ratio of G-CSF is 80% or more, preferably 85% or more, more preferably Means to keep it above 90%.
  • a protein prefilled syringe preparation can be stably stored at room temperature for a long period of time.
  • a stable protein prefilled syringe formulation comprising a stopper in which the plastic film of the present invention is laminated at least on the protein solution contacting surface is a stable protein prefilled syringe formulation. More stable than syringe formulations.
  • a protein prefilled syringe preparation can be stably stored at room temperature for a long period of time.
  • the protein is obtained by a genetic recombination method, it is unstable compared to natural proteins, and should be stably stored at room temperature for a long period of time by using the prefilled syringe preparation of the present invention.
  • G-CSF granulocyte colony stimulating factor
  • the evaluation of the preparation was performed by determining the content of G-CSF using RP-HPLC analysis.
  • Example 1 G-CSF solution at 40 ° C for 2 weeks accelerated test
  • the G-CSF used in this example is a recombinant protein having a sugar chain (rG-CSF) produced in CHO cells.
  • Container form a recombinant protein having a sugar chain (rG-CSF) produced in CHO cells.
  • a PTFE-laminated glass syringe is filled with the above dispensing solution, and the stopper is sealed and stoppered by attaching a PTFE sheet to the liquid contacting surface of a WEST stop stopper (Material: bromobutyl rubber PH4023 / 50). .
  • Untreated stopper A syringe filled with the above preparation liquid and sealed with a stopper (material: bromobutyl rubber PH4023 / 50) manufactured by WEST.
  • PTFE laminating stock A PTFE sheet with a PTFE sheet attached to the liquid contacting surface of a WEST stopper (material: PTFE is peeled from bromobutyper), and the liquid contacting surface is used. Was peeled off. A glass syringe filled with the above dispensing solution and sealed and stoppered using this stopper.
  • Example 2 Storage stability test of G-CSF solution formulation at 25 ° C and 10 ° C
  • each container form containing the solution preparation prepared by aseptic preparation and filtration was stored at 25 ° C and 10 ° C for a long time. Thereafter, the residual ratio was calculated in the same manner as in Example 1. Tables 3 and 4 show the results.
  • EPO solution preparations of the following two concentrations (1500 IUZmL and 48000 IU / mL) were prepared, filled aseptically into containers equipped with PTFE laminate stoppers (BD), and stoppered. Accelerated tests were performed at 50 ° C and 40 ° C, and long-term storage tests were performed at 25 ° C and 10 ° C, and the residual rates were calculated respectively. The results are shown in Table 5-8. Formulation: 1500IU L 48000IU / mL

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une préparation stabilisée de seringue préalablement remplie de protéine équipée d'un bouchon présentant un film en plastique stratifié au moins au niveau de la surface étant en contact avec la solution protéique.
PCT/JP2000/009309 1999-12-28 2000-12-27 Preparation de seringue prealablement remplie de proteine et procede de stabilisation WO2001047544A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22275/01A AU2227501A (en) 1999-12-28 2000-12-27 Protein-prefilled syringe preparation and method of stabilizing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP37518699 1999-12-28
JP11/375186 1999-12-28

Publications (1)

Publication Number Publication Date
WO2001047544A1 true WO2001047544A1 (fr) 2001-07-05

Family

ID=18505119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/009309 WO2001047544A1 (fr) 1999-12-28 2000-12-27 Preparation de seringue prealablement remplie de proteine et procede de stabilisation

Country Status (2)

Country Link
AU (1) AU2227501A (fr)
WO (1) WO2001047544A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012228335A (ja) * 2011-04-26 2012-11-22 Taisei Kako Co Ltd プレフィルドシリンジ用弾性シール体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5219435Y2 (fr) * 1971-06-11 1977-05-04
JPS5532602Y2 (fr) * 1972-05-31 1980-08-04
JPS62139668A (ja) * 1985-12-16 1987-06-23 株式会社大協精工 積層した注射器用栓
EP0264273A2 (fr) * 1986-10-15 1988-04-20 Daikyo Gomu Seiko Ltd. Piston composite pour seringue
EP0879611A2 (fr) * 1997-05-22 1998-11-25 Daikyo Seiko, Ltd. Piston pour seringue et seringue préremplie
JPH11146910A (ja) * 1997-04-25 1999-06-02 Minoru Terano 生体適合性ポリオレフィン成形品、及び生体適合性高分子材料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5219435Y2 (fr) * 1971-06-11 1977-05-04
JPS5532602Y2 (fr) * 1972-05-31 1980-08-04
JPS62139668A (ja) * 1985-12-16 1987-06-23 株式会社大協精工 積層した注射器用栓
EP0264273A2 (fr) * 1986-10-15 1988-04-20 Daikyo Gomu Seiko Ltd. Piston composite pour seringue
JPH11146910A (ja) * 1997-04-25 1999-06-02 Minoru Terano 生体適合性ポリオレフィン成形品、及び生体適合性高分子材料
EP0879611A2 (fr) * 1997-05-22 1998-11-25 Daikyo Seiko, Ltd. Piston pour seringue et seringue préremplie

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012228335A (ja) * 2011-04-26 2012-11-22 Taisei Kako Co Ltd プレフィルドシリンジ用弾性シール体
EP2703024A1 (fr) * 2011-04-26 2014-03-05 Taisei Kako Co., Ltd. Obturateur élastique pour seringue préremplie
EP2703024A4 (fr) * 2011-04-26 2014-10-22 Taisei Kako Co Obturateur élastique pour seringue préremplie

Also Published As

Publication number Publication date
AU2227501A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
JP6076226B2 (ja) タンパク質溶液製剤およびその安定化方法
JP5490972B2 (ja) タンパク質注射製剤
JP4607336B2 (ja) 長期安定化製剤
JP4607010B2 (ja) タンパク質含有安定化製剤
US9125893B2 (en) Highly concentrated anti-CD40 antibody pharmaceutical preparation
CZ228299A3 (cs) Stabilizovaný kapalný přípravek obsahující interferon
JP2007204498A (ja) 長期安定化製剤
US7998929B2 (en) Solution preparations stabilized over long time
KR100389726B1 (ko) 안정한 과립구 콜로니-자극 인자 함유 제제
JP5271481B2 (ja) タンパク質溶液製剤およびその安定化方法
WO2001047544A1 (fr) Preparation de seringue prealablement remplie de proteine et procede de stabilisation
KR100265222B1 (ko) 트롬보포이에틴조성물
WO2000015241A1 (fr) Preparation d'une solution proteinique et son procede de stabilisation
JP6445169B2 (ja) α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642